Collagen Targeted Imaging Probes
AssigneeThe General Hospital Corporation
InventorsPaulene Desogere, Peter Caravan
Life of this patent
Estimating the term…
Abstract
Disclosed herein are collagen-targeted imaging agents for positron emission tomography and related imaging methods using the collagen-targeted imaging agents. The collagen-targeted imaging agent is a cyclic polypeptide comprising a cyclic main body, wherein the cyclic main body comprises at least one S—S bond; at least two branches, wherein each of the at least two branches comprises at least three amino acids; and a linker, wherein the linker is capable of linking an imaging reporter.
Claims32
A cyclic polypeptide of formula
- wherein R1 comprises at least one amino acid;
- wherein R2 comprises at least one amino acid;
- wherein R3 comprises at least one amino acid;
- wherein R4 comprises at least one amino acid;
- wherein R5 comprises at least one amino acid;
- wherein R6 comprises at least one amino acid;
- wherein the cyclic polypeptide further comprises a linker that is capable of linking an imaging reporter, and
- wherein R1 includes at least one amino acid selected from the group consisting of lysine (K), tyrosine (Y), glutamic acid (E), aspartic acid (D), arginine (R) and leucine;
- or
- a cyclic polypeptide of formula (I):
- wherein:
- R1 is lysine (K)-NODAGA,
- R2 is NODAGA-glycine (G)-lysine (K)[glycine (G)-NODAGA],
- R3 is leucine (L),
- R4 is tyrosine (Y),
- R5 is 4,4-biphenylalanine (BIP) and
- R6 is threonine (T), and
- wherein the cyclic polypeptide comprises an imaging reporter;
- or
- a cyclic peptide of formula (I):
- wherein:
- R1 is tyrosine (Y),
- R2 is NODAGA-glycine (G)-glutamine(Q),
- R3 is leucine (L),
- R4 is tyrosine (Y),
- R5 is glycine (G),
- R6 is threonine (T), and
- wherein the cyclic polypeptide comprises an imaging reporter;
- or
- a cyclic peptide of formula (I):
- wherein:
- R1 is aspartic acid (D),
- R2 is NODAGA-glycine (G)-glutamine(Q),
- R3 is leucine (L),
- R4 is 2-naphthylalanine (2-Nal),
- R5 is glycine (G) and
- R6 is threonine (T), and
- wherein the cyclic polypeptide comprises an imaging reporter;
- or
- a cyclic polypeptide of formula (I):
- wherein:
- R1 is arginine (R),
- R2 is NODAGA-glycine (G)-glutamine(Q),
- R3 is phenylalanine (F),
- R4 is tyrosine (Y),
- R5 is glycine (G) and
- R6 is threonine (T), and
- wherein the cyclic polypeptide comprises an imaging reporter;
- or
- a cyclic polypeptide of formula (I):
- wherein:
- R1 is leucine (L),
- R2 is NODAGA-glycine (G)-glutamine(Q),
- R3 is leucine (L),
- R4 is tyrosine (Y),
- R5 is glycine (G),
- R6 is tyrosine (Y), and
- wherein the cyclic polypeptide comprises an imaging reporter;
- or
- a cyclic polypeptide of formula (I):
- wherein:
- R1 is glutamic acid (E),
- R2 is NODAGA-glycine (G)-glutamine(Q),
- R3 is leucine (L),
- R4 is tyrosine (Y),
- R5 is 4,4-biphenylalanine (BIP),
- R6 is threonine (T), and
- wherein the cyclic polypeptide comprises an imaging reporter.
(canceled)
-9. (canceled)
A compound having the following structure:
- or pharmaceutically acceptable salt thereof.
-17. (canceled)
A cyclic polypeptide comprising:
- (a) a cyclic main body, wherein the cyclic main body comprises at least one S—S bond;
- (b) at least two branches, wherein each of the at least two branches comprises at least three amino acids;
- and
- (c) a metal chelating group capable of binding an imaging reporter, the metal chelating group being covalently linked directly to the body or at least one of the branches, or the metal chelating group being linked to the body or at least one of the branches via a linker.
(canceled)
-26. (canceled)
-30. (canceled)
-53. (canceled)
-56. (canceled)
-62. (canceled)
-66. (canceled)
-70. (canceled)
-74. (canceled)
Dependencies are inferred from the claim text.